Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
3 Great Stocks You Can Buy With $50 Right Now
06:17am, Wednesday, 20'th Oct 2021
You can pick up small pieces of these great businesses for next to nothing.
3 Biotech Stocks That Could Rise 90% or More, According to Wall Street
06:21am, Sunday, 17'th Oct 2021
These stocks are expected to put up big gains in a short amount of time.
New Strong Sell Stocks for October 14th
12:38pm, Thursday, 14'th Oct 2021
ARNC, BSET, FMS, OCUL, and PTGX have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2021.
Why Are Ocular Therapeutix Shares Trading Higher Today?
03:30pm, Monday, 11'th Oct 2021
The FDA has approved Ocular Therapeutix Inc's (NASDAQ: OCUL) supplemental application to broaden the Dextenza label. The approval now adds an indication for ocular itching associated with allergic
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera
Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts
06:45am, Monday, 13'th Sep 2021
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera
This Exciting Biopharma Could Earn You 55% in 12 Months
07:38am, Sunday, 22'nd Aug 2021
When patients see more clearly, so too should investors.
4 Reasons I Just Bought Ocular Therapeutix Stock
06:21am, Saturday, 21'st Aug 2021
This company's drug delivery technology just isn't getting the appreciation it deserves right now.
Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More
12:56pm, Tuesday, 10'th Aug 2021
With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.
Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q2 2021 Results - Earnings Call Transcript
09:22pm, Monday, 09'th Aug 2021
Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q2 2021 Results - Earnings Call Transcript
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
06:28pm, Monday, 09'th Aug 2021
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -25.00% and 0.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix: Why I'm Buying The Dip
06:07am, Monday, 09'th Aug 2021
OCUL has dropped substantially since a December 2020 stock offering.
Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases
10:09am, Friday, 06'th Aug 2021
Ocular Therapeutix Inc (NASDAQ: OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have terminated the option and license agreement collaboration. The termination is effective immediately.
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera
After Plunging 19.8% in 4 Weeks, Here's Why the Trend Might Reverse for Ocular Therapeutix (OCUL)
11:30am, Tuesday, 27'th Jul 2021
The heavy selling pressure might have exhausted for Ocular Therapeutix (OCUL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
